Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Raynaud's Phenomenon (Secondary)”

30 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 30 results

Testing effectiveness (Phase 2)Study completedNCT02688270
What this trial is testing

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

Who this might be right for
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Covis Pharma S.à.r.l. 65
Large-scale testing (Phase 3)Study completedNCT01280266
What this trial is testing

Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon

Who this might be right for
Raynaud Phenomenon
Seoul National University Hospital 29
Post-approval studies (Phase 4)Study completedNCT00048763
What this trial is testing

Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Who this might be right for
Raynaud's Disease
Otsuka America Pharmaceutical 75
Testing effectiveness (Phase 2)Study completedNCT04388176
What this trial is testing

Cold Challenge With C21 in RP

Who this might be right for
Raynaud PhenomenonSystemic Sclerosis
Vicore Pharma AB 20
Testing effectiveness (Phase 2)Ended earlyNCT04915950
What this trial is testing

Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Pfizer 13
Large-scale testing (Phase 3)Study completedNCT04040322
What this trial is testing

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Civi Biopharma, Inc. 198
Very early researchStudy completedNCT03027674
What this trial is testing

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Who this might be right for
Raynaud Phenomenon Due to TraumaRaynaud DiseaseSystem; Sclerosis+3 more
Pontificia Universidad Catolica de Chile 10
Testing effectiveness (Phase 2)Study completedNCT00707187
What this trial is testing

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

Who this might be right for
Systemic Sclerosis
University of Medicine and Dentistry of New Jersey 120
Testing effectiveness (Phase 2)Study completedNCT00378521
What this trial is testing

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

Who this might be right for
Raynaud's DiseaseRaynaud's Disease Secondary to SclerodermaRaynaud's Disease Secondary to Autoimmune Disease
MediQuest Therapeutics 15
Not applicableUnknownNCT01378845
What this trial is testing

Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on Hands

Who this might be right for
Raynaud's PhenomenonSkin Necrosis
Christoph Hehrlein 30
Not applicableStudy completedNCT00822354
What this trial is testing

Tadalafil for the Treatment of Raynaud's

Who this might be right for
Raynaud
Northwestern University 10
Testing effectiveness (Phase 2)Ended earlyNCT01315899
What this trial is testing

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Who this might be right for
Raynaud's Phenomenon
Orion Corporation, Orion Pharma 15
Testing effectiveness (Phase 2)Study completedNCT03867097
What this trial is testing

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Who this might be right for
Raynaud Phenomenon Secondary to Systemic Sclerosis
Civi Biopharma, Inc. 34
Large-scale testing (Phase 3)UnknownNCT00577304
What this trial is testing

A Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Who this might be right for
Raynaud's DiseaseRaynaud's Disease Secondary to SclerodermaRaynaud's Disease Secondary to Other Autoimmune Disease
MediQuest Therapeutics 200
Testing effectiveness (Phase 2)Study completedNCT01090492
What this trial is testing

PF-00489791 For The Treatment Of Raynaud's

Who this might be right for
Raynaud's DiseasePeripheral Vascular Disease
Pfizer 243
Large-scale testing (Phase 3)Study completedNCT03717961
What this trial is testing

Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud Phenomenon Secondary to Systemic Sclerosis
Assistance Publique - Hôpitaux de Paris 91
Not applicableStudy completedNCT03211325
What this trial is testing

Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.

Who this might be right for
Raynaud's Phenomenon Isolated PrimaryRaynaud's Phenomenon (Secondary)Healthy
University Hospital, Grenoble 29
Testing effectiveness (Phase 2)Study completedNCT02228850
What this trial is testing

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) 35
Large-scale testing (Phase 3)Study completedNCT00004786
What this trial is testing

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Systemic SclerosisRaynaud Disease
National Center for Research Resources (NCRR) 200
Testing effectiveness (Phase 2)UnknownNCT02356809
What this trial is testing

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Who this might be right for
Secondary Raynaud's Phenomenon
Artgen Biotech 30
Load More Results